Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
GI Innovation, Inc.
Merck Sharp & Dohme LLC
Astellas Pharma Inc
Mayo Clinic
Neonc Technologies, Inc.
Merck Sharp & Dohme LLC
University of California, Davis
Inhibrx Biosciences, Inc
Astellas Pharma Inc
Dana-Farber Cancer Institute
Merck Sharp & Dohme LLC
NuCana plc
Aprea Therapeutics
Hoosier Cancer Research Network
RAPT Therapeutics, Inc.
Salubris Biotherapeutics Inc
Sumitomo Pharma America, Inc.
Evopoint Biosciences Inc.
Genocea Biosciences, Inc.
Silverback Therapeutics
Incyte Corporation
Incyte Corporation
Rainier Therapeutics
Eli Lilly and Company